Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ResMed’s cloud-connected ventilators and proprietary software generate reams of regulatory data, making its disclosures dense even for seasoned analysts. If you have ever sifted through a 300-page report looking for AirSense sales or FDA recall language, you know the challenge. Stock Titan surfaces what matters in seconds, turning complicated respiratory-device statements into clear talking points.
Our AI reads every ResMed annual report 10-K simplified, scans each ResMed quarterly earnings report 10-Q filing, and flags fresh ResMed 8-K material events explained the moment they hit EDGAR. Want management sentiment? Real-time alerts track ResMed insider trading Form 4 transactions and the companion ResMed executive stock transactions Form 4 data stream. Policy votes and pay packages are covered in the ResMed proxy statement executive compensation section. All documents sit one click away, while concise paragraphs answer most popular searches such as understanding ResMed SEC documents with AI or “How do I find the latest ResMed Form 4 insider transactions real-time?”
Use these insights to:
- Compare PAP device revenue across quarters with AI-generated charts
- Spot insider buying ahead of new mask launches using our ResMed earnings report filing analysis
- Monitor product-recall language or patent disputes the minute they appear in an 8-K
ResMed Inc. Chairman and CEO Michael J. Farrell reported an option exercise and share sale. On 12/08/2025, he exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share, converting them into the same number of common shares.
On the same date, he sold 4,991 ResMed common shares at a weighted average price of $251.4117 per share under a Rule 10b5-1 trading plan adopted on October 31, 2024. After these transactions, he directly owned 466,223 ResMed shares, held 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust, and beneficially owned 54,903 stock options with underlying ResMed shares.
Michael Farrell has filed a notice under Rule 144 indicating a planned sale of 4,991 shares of RMD common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $1,254,795.75. The filing states that 145,966,294 common shares were outstanding at the time of the notice, providing context for the size of this planned sale. The shares to be sold were acquired on 12/08/2025 via an option granted on 11/21/2019 and paid for in cash. The notice also lists prior sales over the past three months, including separate transactions of 8,009, 8,009, and 8,011 common shares, each with disclosed gross proceeds.
ResMed Inc. director reports planned stock sale. A reporting person serving as a director of ResMed Inc. (ticker RMD) sold 2,000 shares of ResMed common stock on 12/03/2025 at a price of $251.47 per share. The transaction was coded as a sale and was made under a Rule 10b5-1 trading plan adopted on August 12, 2025, which allows pre-arranged trades according to preset instructions. Following this sale, the insider directly beneficially owns 68,773 shares of ResMed common stock, reflecting the remaining stake reported in this filing.
Peter C Farrell has filed a notice to sell up to 2,000 shares of common stock under Rule 144. The planned sale has an aggregate market value of $502,860, to be executed through Merrill Lynch on or around 12/03/2025 on the NYSE. The filing notes that 44,448,959 shares of this class are outstanding.
The 2,000 shares being sold were acquired through stock option exercises on three dates between 2014 and 2015, all paid in cash. The notice also reports that the same seller disposed of 2,000 common shares in the past three months, on 11/12/2025, generating gross proceeds of $504,020.
ResMed Inc. reported an insider stock sale by its Global General Counsel. The Form 4 shows that officer Michael J. Rider sold 50 shares of ResMed common stock on 12/01/2025 at a price of $244.16 per share. After this transaction, he beneficially owned 9,791 shares of ResMed common stock directly.
The filing notes that the sale was made under a pre-arranged Rule 10b5-1 trading plan that was adopted on February 28, 2025, which is designed to allow insiders to sell shares according to a set schedule.
ResMed Inc.'s Chief Financial Officer reports a routine stock sale. On 12/01/2025, the CFO sold 1,000 shares of ResMed common stock at a price of $244.16 per share in an open market transaction. The filing notes that this sale was conducted under a pre-arranged Rule 10b5-1 trading plan that was adopted on February 19, 2025, which is designed to allow insider transactions under preset instructions.
After this transaction, the CFO continues to beneficially own 87,495 ResMed shares, held directly. The filing does not report any derivative securities transactions, indicating that this update relates only to common stock ownership.
An insider of RMD has filed a notice to sell 1,000 shares of common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $244,160. These shares were acquired on 11/11/2022 through restricted stock vesting as compensation from the issuer.
In the past three months, the same seller reported three additional sales: 3,000 shares on 09/02/2025 for gross proceeds of $812,310, 3,000 shares on 10/01/2025 for $823,080, and 3,000 shares on 11/03/2025 for $742,620. The issuer lists 145,966,294 shares of common stock outstanding, providing scale versus these planned and recent insider sales.
ResMed Inc. (RMD) reported an equity compensation grant to its Chairman and CEO on a Form 4. On 11/24/2025, he received options to purchase 33,288 shares of ResMed common stock at an exercise price of $250.52 per share. These options first become exercisable on 11/11/2026 and vest in three equal annual installments starting on that date, aligning his incentives with longer-term company performance. Following this grant, he beneficially owns 466,223 shares of ResMed common stock held directly.
ResMed Inc. (RMD)1,331 stock options on ResMed common stock with an exercise price of $250.52 per share. These options become exercisable on the earlier of November 11, 2026, or the date of the first annual meeting of stockholders following the grant date, and expire on November 11, 2032.
After this reported transaction, the director beneficially owns 70,773 shares of ResMed common stock directly, as well as 1,331 stock options directly.
ResMed Inc. (RMD) director files Form 4 for planned stock sale. Director Jan De Witte reported selling 2,055 shares of ResMed common stock on 11/25/2025 at a price of $255 per share. After this transaction, De Witte beneficially owns 4,261 shares, held directly.
The sale was coded as an "S" transaction and was carried out under a Rule 10b5-1 trading plan adopted on August 18, 2025, indicating it was pre-arranged under preset instructions rather than a discretionary, one-off trade.
FAQ
What is the current stock price of Resmed (RMD)?
What is the market cap of Resmed (RMD)?
